Shares of biomedical issue Alkermes (ALKS) surged 5% Thursday when the company released blowout results for its September-ending quarter, its fiscal Q2, and issued better guidance than the Street had been expecting. The Dublin-headquartered company earned 17 cents per share in the quarter, 143% more than the year-earlier period and 6 cents more than analysts had estimated. Revenue rose 72% to $124 million, also beating estimates. The sales